Extended Data Fig. 1: Atherogenic Lipid Goal Achievement. | Nature Medicine

Extended Data Fig. 1: Atherogenic Lipid Goal Achievement.

From: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

Extended Data Fig. 1

Achievement of treatment goals for LDL cholesterol, non-HDL cholesterol and apoB in patients treated with placebo or obicetrapib at days 84 and 365. The primary endpoint of the study was the percentage change in LDL cholesterol from baseline to day 84. Error bars represent 95% confidence intervals. Sample size: n = 118 (placebo), n = 236 (obicetrapib) representing biological replicates (individual patients). apoB, apolipoprotein B; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Back to article page